(R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine

Biological Psychiatry

Volumn 82, Issue 5, 2017, Pages e43-e44

  Yang, Chun ^a   Qu, Youge ^a   Abe, Masahito ^b   Nozawa, Dai ^b   Chaki, Shigeyuki ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HYDROXYNORKETAMINE; KETAMINE; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; 6-HYDROXYNORKETAMINE; ANTIDEPRESSANT AGENT;

ADULT; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; LETTER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DOMINANT-SUBORDINATE RELATIONSHIP; INFLAMMATION; MENTAL STRESS; STEREOISOMERISM; TIME FACTOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOMINANCE-SUBORDINATION; INFLAMMATION; KETAMINE; LIPOPOLYSACCHARIDES; MALE; MICE, INBRED C57BL; STEREOISOMERISM; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 85009344295     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.12.020     Document Type: Letter

References (10)

1. Krystal, J.H., Sanacora, G., Duman, R.S., Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry 73 (2013), 1133–1141.
2. Hashimoto, K., R-Ketamine: A rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46 (2016), 2449–2451.
3. Hashimoto, K., Ketamine's antidepressant action: Beyond NMDA receptor inhibition. Expert Opin Ther Targets 173 (2016), 1389–1392.
4. Zhang, J.C., Li, S.X., Hashimoto, K., R(−)-Ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116 (2014), 137–141.
5. Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Yao, W., Ma, M., et al. R-Ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry, 5, 2015, e632.
6. Yang, B., Ren, Q., Ma, M., Chen, Q.X., Hashimoto, K., Antidepressant effects of (+)-MK-801 and (−)-MK-801 in the social defeat stress model. Int J Neuropsychopharmacol, 19(12), 2016.
7. Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
8. Zhang, J.C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol, 18, 2014, pyu077.
9. Shirayama, Y., Hashimoto, K., Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267 (2017), 177–182.
10. Singh, J.B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., et al. Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 50 (2016), 424–431.